These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3460809)

  • 21. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.
    Iguchi H; Tone H; Ishikura T; Takeuchi T; Umezawa H
    Cancer Chemother Pharmacol; 1985; 15(2):132-40. PubMed ID: 4017162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
    Israel M; Wilkinson PM; Pegg WJ; Frei E
    Cancer Res; 1978 Feb; 38(2):365-70. PubMed ID: 620407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas.
    Lazo JS; Schwartz PE
    Gynecol Oncol; 1985 May; 21(1):65-72. PubMed ID: 3988127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
    Sweatman TW; Israel M
    Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.
    Preiss R; Sohr R; Kittelmann B; Müller E; Haase D
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):156-64. PubMed ID: 2714916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography.
    Shinozawa S; Mimaki Y; Araki Y; Oda T
    J Chromatogr; 1980 Aug; 196(3):463-9. PubMed ID: 7430305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative determination of adriamycin in rat hepatocytes using a volatile extraction buffer, HPLC and fluorescence detection.
    Mahdadi R; Pommery N; Pommery J; Lhermitte M
    Biomed Chromatogr; 1987; 2(3):91-4. PubMed ID: 3507221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines.
    Krishan A; Ganapathi R
    Cancer Res; 1980 Nov; 40(11):3895-900. PubMed ID: 6937236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
    Cummings J; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and tissue disposition of mitozolomide in mice.
    Brindley CJ; Antoniw P; Newlands ES
    Br J Cancer; 1986 Jan; 53(1):91-7. PubMed ID: 3456242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative histochemical study of adriamycin and adriamycinol in rat liver and heart.
    Mazzanti L; Breschi MC; Scalori V; Giovannini L; Mian M
    In Vivo; 1988; 2(3-4):189-93. PubMed ID: 2979836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.
    Willmott N; Cummings J; Marley E; Smyth JF
    Biochem Pharmacol; 1990 Mar; 39(6):1055-62. PubMed ID: 2322293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.
    Bolanowska W; Gessner T; Preisler H
    Cancer Chemother Pharmacol; 1983; 10(3):187-91. PubMed ID: 6574828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D.
    Terasaki T; Iga T; Sugiyama Y; Sawada Y; Hanano M
    J Pharmacobiodyn; 1984 May; 7(5):269-77. PubMed ID: 6470925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of adriamycin and its fluorescent metabolites in human plasma by HPLC.
    Mahdadi R; Lhermitte M; Lafitte JJ
    Biomed Chromatogr; 1987 Feb; 2(1):38-40. PubMed ID: 3508093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters.
    Kubo T; Sugita T; Shimose S; Nitta Y; Ikuta Y; Murakami T
    Int J Oncol; 2000 Aug; 17(2):309-15. PubMed ID: 10891540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit.
    Gewirtz DA; Yanovich S
    Biochem Pharmacol; 1987 Jun; 36(11):1793-8. PubMed ID: 3579974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The consequences of doxorubicin quinone reduction in vivo in tumour tissue.
    Cummings J; Willmott N; Hoey BM; Marley ES; Smyth JF
    Biochem Pharmacol; 1992 Dec; 44(11):2165-74. PubMed ID: 1472081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. General and cardiac toxicity of adriamycinol in rats.
    Danesi R; Del Tacca M; Della Torre P; Bernardini C
    Anticancer Res; 1986; 6(5):967-72. PubMed ID: 3800337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.